Company profile: Flexus BioSciences
1.1 - Company Overview
Company description
- Provider of novel anti-cancer therapeutics created, developed, and commercialized through an innovative application of unexploited insights in immunology; privately-held biopharmaceutical company founded in 2013 and headquartered in San Carlos, California.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Flexus BioSciences
Bilthoven Biologicals
HQ: The Netherlands
Website
- Description: Provider of pharmaceutical products manufacturing services and vaccine/diagnostic solutions, including inactivated polio vaccine (IPV), pandemic preparedness vaccine facilities in Europe (capacity over 300 million doses annually), SIILTIBCY tuberculosis skin test, BCG for bladder cancer and TB vaccination, DTP vaccine (diphtheria, tetanus, polio), and tetanus vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bilthoven Biologicals company profile →
Visterra
HQ: United States
Website
- Description: Provider of therapeutic and diagnostic products and R&D for infectious diseases, leveraging structure-based design informed by glycobiology and glycochemistry. Pipeline includes Sibeprenlimab (VIS649) for IgA nephropathy, VIS171 (modified IL-2) to activate Tregs, and VIS513 for dengue. Platforms: HIEROTOPE for epitope selection/design and ViSTAR Fc modifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visterra company profile →
MacroGenics
HQ: United States
Website
- Description: Provider of immunotherapeutics, including antibody-drug conjugates and DART bispecifics targeting B7-H3, PD-1×CTLA-4 and CD123, to treat metastatic castration-resistant prostate cancer, advanced solid tumors, CD123-positive neoplasms (AML, MDS) and multiple cancers; programs include vobramitamab duocarmazine, lorigerlimab, MGD024, MGC026, MGC028 and enoblituzumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MacroGenics company profile →
Vaxart
HQ: United States
Website
- Description: Provider of oral vaccine pills and vaccine technology for infectious diseases, including COVID-19 (Phase II, room-temperature stable for easier global distribution), norovirus (Phase 1), influenza (Phase 1 completed for H1N1 and influenza B), RSV (targeting vulnerable populations), and an HPV therapeutic vaccine for types 16 and 18, built on the VAAST™ platform using Ad5 to deliver antigens and adjuvants to mucosal cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxart company profile →
Quest PharmaTech
HQ: Canada
Website
- Description: Provider of antibody-based immunotherapeutic products for cancer and photodynamic therapy technology for oncology and dermatology, including Oregovomab, an antibody-based immunotherapy in clinical trials for ovarian cancer, and truncated MUC16-targeting Mab AR 9.6 as a theranostic agent.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quest PharmaTech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Flexus BioSciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Flexus BioSciences
2.2 - Growth funds investing in similar companies to Flexus BioSciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Flexus BioSciences
4.2 - Public trading comparable groups for Flexus BioSciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →